Abstract:Cytokine storm syndrome (CSS) is a life-threatening condition characterized by excessive activation of T cells and uncontrolled inflammation, mostly described in patients with familial hemophagocytic lymphohistiocytosis and certain systemic auto-inflammatory diseases, such as systemic juvenile idiopathic arthritis (sJIA). Defects in T cell cytotoxicity as a mechanism for uncontrolled inflammation following viral infections fail to represent the whole spectrum of CSS. Evidence implicates dysregulated innate immune responses, especially activation of monocytes and macrophages, in patients with CSS. However, the direct contribution of monocytes/macrophages to CSS development and the signaling pathways involved in their activation have not been formally investigated. We find that depletion of monocytes/macrophages during early stages of CSS development, by clodronate-liposomes or neutralizing anti-CSF1 antibody, reduces mortality and inflammatory cytokine levels in two CSS mouse models, one dependent on T cells and the second induced by repeated TLR9 stimulation. We further demonstrate that activation of Plcγ2 in myeloid cells controls CSS development by driving macrophage pro-inflammatory responses. Intriguingly, the Plcγ2 downstream effector Tmem178, a negative modulator of calcium levels, acts in a negative feedback loop to restrain inflammatory cytokine production. Genetic deletion of Tmem178 leads to pro-inflammatory macrophage polarization in vitro and more severe CSS in vivo. Importantly, Tmem178 levels are reduced in macrophages from mice with CSS and after exposure to plasma from sJIA patients with active disease. Our data identify a novel Plcγ2/Tmem178 axis as a modulator of inflammatory cytokine production by monocytes/macrophages. We also find that loss of Tmem178 accentuates the pro-inflammatory responses in CSS.

IL-1 Family Blockade in Cytokine Storm Syndromes

IL-6 Blockade in Cytokine Storm Syndromes

Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome

Therapeutic Targeting of Interleukin-6 for the Treatment of COVID-19.

JAK Inhibitors in Cytokine Storm Syndromes

Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis.

Understanding of Cytokines and Targeted Therapy in Macrophage Activation Syndrome.

Other Immunomodulatory Treatment for Cytokine Storm Syndromes

Monocytic Phagocytes in the Immunopathogenesis of Cytokine Storm Syndromes

Looking into the IL-1 of the storm: are inflammasomes the link between immunothrombosis and hyperinflammation in cytokine storm syndromes?

Autoinflammatory Contributors to Cytokine Storm

Criteria for Cytokine Storm Syndromes

Clinical Features of Cytokine Storm Syndrome

CD8+ T Cell Biology in Cytokine Storm Syndromes

Cytokines in Cytokine Storm Syndrome

Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis

Neutrophil–macrophage communication via extracellular vesicle transfer promotes itaconate accumulation and ameliorates cytokine storm syndrome

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model

Blocking interleukin-1 in rheumatic diseases

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19